Menu

Wilhelm Group

Group leader

Prof. Christoph Wilhelm

Prof. Christoph Wilhelm, Ph.D.


Tel.: +49 228 287-51721
Fax: +49 228 287-16094

North Zone, Building No. 12
1st Floor, Room 1G402

A major societal challenge in the Western world is the dramatic increase in chronic inflammatory disorders manifesting at barrier sites, including allergies, asthma (lung), psoriasis (skin), and inflammatory bowel disease (IBD; intestine). Recent advances identified a new group of innate immune cells primarily residing at such barrier surfaces, which were named innate lymphoid cells (ILC). Three distinct ILC subsets have been described to reside in the gut, lung and skin. Type 1 ILC (ILC1) express the transcription factor T-bet, produce the cytokine interferon (IFN)-γand are implicated in protecting against intracellular pathogens such as Toxoplasma gondii ILC2 express the transcription factor GATA-3 and produce the cytokines IL-5, IL-9, IL-13 and amphiregulin. ILC3 are characterized by the expression of the transcription factor Rorgt and the cytokine IL-22. Thus, the major task of ILC is the protection and maintenance of the tissue barrier. However, chronic activation of ILC can promote inflammation and contribute to inflammatory disorders manifesting at barrier sites. In general, the etiology of barrier diseases is poorly understood but changes in life-style coinciding with westernization, such as abundant nutritional uptake and increased hygiene, leading to an overall absence of parasitic infections are suggested to play a role in disease development.

A major current goal of our research is to understand the difference between protective and pathogenic ILC function by studying the metabolic regulation of ILC in health and disease. In particular we work under the assumption that the metabolic adaptation of ILC, which allows their survival in nutrient deprived environments (e.g. starvation, vitamin A deficiency) is an important evolutionary restraint lost in Industrialized countries. Our recent data suggests that protective ILC2 mediated anti-helminth immune responses are dependent on fatty acid metabolism but not glycolysis and that vitamin A deficiency increases fatty acid oxidation in ILC2. Basing the function of ILC2 elicited in the context of helminth infection on fatty acid metabolism may have been important to mediate tissue repair and worm expulsion in settings of malnutrition and low glucose. However, this scenario dictated by chronic helminth infections and low nutrient availability has dramatically changed in the western world and it is completely unknown whether both protective and pathogenic ILC responses underlie a similar metabolic control. Currently, we are attempting to identify metabolic pathways driving disease pathology in order to identify novel pharmacological inhibitors that could be used to treat disease. In addition, by mimicking situations of nutrient deprivation we are currently testing different dietary intervention strategies with the aim to identify novel therapeutic treatments to target ILC-mediated pathologies. 

Thus, with our research we aim to contribute to the understanding of one major societal challenge, the dramatic increase in chronic inflammatory disorders and to identify novel potential targets for therapeutics as well as the possibility of dietary interventions strategies for their treatment.

 

Group members

Dr. David Fernando Colón Morelo, PostDoc

Tel.: +49 228 287-51730

Sara Dörken, WHF
Tel.: +49 228 287-51730

Maria Dovermann, Doctoral candidate

Tel.: +49 228 287-51730

Dr. Fotis Karagiannis, PostDoc

Tel.: +49 228 287-51720

Alexander Kazakov, Doctoral candidate

Tel.: +49 228 287-51730

Marcel Michla, Doctoral candidate

Tel.: +49 228 287-51720

Lukas Petri, SHK
Tel.: +49 228 287-51730

Dr. Laura Surace, PostDoc

Tel.: +49 228 287-51720

Maria Rafailia Theodorou, Doctoral candidate

Tel.: +49 228 287-51730

Patricia Weiss, Technician
Tel.: +49 228 287-51720

Tim Wellinghof, TA
Tel.: +49 228 287-51720

 

Jobs available at the Wilhelm Group

We are always interested in recruiting highly motivated students and postdocs and thus encourage applications from prospective candidates at anytime.

Information gemäß § 6 Medizinprodukte-Betreiberverordnung "Beauftragter für Medizinproduktesicherheit"

Sehr geehrte Damen und Herren,

gemäß § 6 Medizinprodukte-Betreiberverordnung steht Ihnen das Universitätsklinikum Bonn im Zusammenhang mit Meldungen über Risiken von Medizinprodukten, Informationen zu Rückrufen oder Warn- und Sicherheitshinweisen sowie bei der Umsetzung von notwendigen korrektiven Maßnahmen unter folgender E-Mailadresse zur Verfügung:

Diese E-Mailadresse richtet sich vorzugsweise an Kontaktpersonen von Behörden, Herstellern und Vertreibern von Medizinprodukten.

This website is using cookies to provide a good browsing experience.

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

This website is using cookies to provide a good browsing experience.

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

Your cookie preferences have been saved.